<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03559686</url>
  </required_header>
  <id_info>
    <org_study_id>RA0039</org_study_id>
    <nct_id>NCT03559686</nct_id>
  </id_info>
  <brief_title>Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)</brief_title>
  <official_title>Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Arthritis (RA) Who Participated in Open Label Studies C87015, C87028 and C87051</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <brief_summary>
    <textblock>
      The objective of this Named Patient Program (NPP) is to provide continued availability of&#xD;
      Certolizumab Pegol (CZP) to adult Rheumatoid Arthritis (RA) patients who participated in the&#xD;
      open label studies C87015 (CDP870 015), C87028 (CDP870-028) and C87051 (CDP870-051).&#xD;
      Physicians may use the option to continue offering patients CZP treatment or to transition&#xD;
      patients off CZP to a standard care regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certolizumab Pegol</intervention_name>
    <description>The recommended maintenance dose of CimziaÂ® (Certolizumab Pegol) for adult patients with Rheumatoid Arthritis (RA) is 200 mg every 2 weeks (single 1 mL injection of 200 mg) .</description>
    <other_name>Cimzia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has/will complete(d) one of the Certolizumab Pegol (CZP) open-label studies (C87015,&#xD;
             C87028, C87051)&#xD;
&#xD;
          -  Is currently taking CZP (last dose within the last 6 weeks for subjects from C87015,&#xD;
             and within the last 4 weeks for subjects from C87028 or C87051)&#xD;
&#xD;
          -  Is informed of the details of this Named Patient Program (NPP), is given ample time&#xD;
             and opportunity to ask questions in order to consider his/her participation in this&#xD;
             NPP and has provided verbal consent to participate, and, if applicable according to&#xD;
             local regulations, has given his/her written informed consent for participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has been treated with any experimental biological or nonbiological therapy other than&#xD;
             CZP within 5 plasma half-lives&#xD;
&#xD;
          -  Current safety concerns for continuing an CZP therapy related to prior biologic&#xD;
             therapy (eg, insufficient wash out period, unresolved adverse events, unresolved&#xD;
             recovery of peripheral B-cell/lymphocyte levels following therapy with B-cell&#xD;
             depleters)&#xD;
&#xD;
          -  Has received live vaccinations including, but not limited to, oral polio, herpes&#xD;
             zoster, measles-mumps-rubella (MMR) or nasal influenza within the last 8 weeks or has&#xD;
             planned live immunizations during the planned period of administration of CZP&#xD;
&#xD;
          -  Serious or life-threatening infection within the last 6 months, including any herpes&#xD;
             zoster infection, and/or any signs of current or recent infection&#xD;
&#xD;
          -  Active or latent tuberculosis (TB): if one or more of the 3 criteria is positive for&#xD;
             evidence of TB infection:&#xD;
&#xD;
               1. A medical history of or current active tuberculosis (TB)&#xD;
&#xD;
               2. A recent (&lt;6 months) chest X-ray with signs consistent with TB infection&#xD;
&#xD;
               3. A recent (&lt;6 months) positive purified protein derivative (PPD) skin test&#xD;
                  (defined as induration or 5 mm or more) and/or an indeterminate or positive&#xD;
                  QuantiFERON-TB Gold or Elispot test.&#xD;
&#xD;
        Patients must be monitored at least annually for active and latent TB by both 1) a chest&#xD;
        X-ray read by a pulmonologist or radiologist and 2) a PPD skin test and/or Elispot/&#xD;
        QuantiFERON TB Gold test.&#xD;
&#xD;
          -  Concurrent known acute or chronic viral hepatitis B or C infection&#xD;
&#xD;
          -  Concurrent known human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Concurrent malignancy or a history of malignant disease&#xD;
&#xD;
          -  History of a lymphoproliferative disorder or any signs or symptoms suggestive of this&#xD;
             disease&#xD;
&#xD;
          -  History of, or suspected or confirmed active demyelinating disease of the central&#xD;
             nervous system&#xD;
&#xD;
          -  History of or concurrent New York Heart Association (NYHA) Class III/IV heart failure&#xD;
&#xD;
          -  Current or recent history of severe, progressive, uncontrolled renal, hepatic,&#xD;
             hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or&#xD;
             cerebral disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UCB Cares</last_name>
    <phone>+1 844 599</phone>
    <phone_ext>2273</phone_ext>
    <email>UCBCares@ucb.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

